CCL20 and melanoma: In murine vaccine model systems analyzing protective or therapeutic efficacy against malaria, tuberculosis, and melanoma, we have studied the impact of fusing vaccine antigen to the chemokine macrophage inflammatory protein 3α (MIP-3α), also known as chemokine (C–C motif) ligand 20 (CCL20).